Valuation: Matinas BioPharma Holdings, Inc.

Market Cap 4.84M 4.23M 3.9M 3.61M 6.84M 461M 6.96M 46.64M 18.32M 227M 18.17M 17.77M 782M P/E 2024
-0.1x
P/E 2025 -0.29x
Enterprise Value 2.19M 1.92M 1.77M 1.63M 3.1M 209M 3.15M 21.15M 8.3M 103M 8.24M 8.06M 354M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.89%
Yield 2024 *
-
Yield 2025 -
1 day+20.46%
1 week+19.21%
Current month+23.42%
1 month-4.99%
3 months+51.06%
6 months+17.34%
Current year+28.89%
1 week 0.61
Extreme 0.612
0.91
1 month 0.6
Extreme 0.6
0.91
Current year 0.48
Extreme 0.48
0.91
1 year 0.48
Extreme 0.48
3.09
3 years 0.47
Extreme 0.4748
44.5
5 years 0.47
Extreme 0.4748
80.5
10 years 0.47
Extreme 0.4748
199.5
Manager TitleAgeSince
Chief Executive Officer 51 2018-03-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 51 2025-03-13
Director/Board Member 52 2025-02-04
Director/Board Member 65 2025-02-12
Date Insider Type Main position Quantity % Market Cap.
25-04-29Free

Chief Executive Officer

70,100 1.3780%
25-04-29Free

Director

11,600 0.2280%
25-04-29Free

Director

11,600 0.2280%
Change 5-day change 1-year change 3-year change Capi.($)
+20.46%+19.21%-26.67%-95.65% 4.84M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average +1.44%+1.67%+46.21%+121.53% 24.12B
Weighted average by Cap. -0.91%-1.46%+55.04%+137.78%

Financials

2024 2025
Net sales - -
Net income -24.25M -21.21M -19.57M -18.07M -34.29M -2.31B -34.87M -234M -91.8M -1.14B -91.06M -89.07M -3.92B -10.34M -9.05M -8.35M -7.71M -14.63M -987M -14.87M -99.72M -39.16M -486M -38.84M -38M -1.67B
Net Debt -4.39M -3.84M -3.54M -3.27M -6.21M -419M -6.31M -42.32M -16.62M -206M -16.48M -16.12M -709M -2.64M -2.31M -2.13M -1.97M -3.74M -252M -3.8M -25.5M -10.01M -124M -9.93M -9.72M -427M
Logo Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Employees
2
Date Price Change Volume
26-07-10 US$0.7553 +20.46% 1,691,770
26-07-09 US$0.6270 +1.79% 21,830
26-07-08 US$0.6160 -0.79% 14,087
26-07-07 US$0.6209 -1.13% 4,690
26-07-06 US$0.6280 -0.89% 29,698

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MTNB Stock